NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication for Q1 FY24 Unaudited Financial Results04-08-2023
04-08-2023
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed the link of the audio recording of the Earnings call for the quarter ended June 30, 2023, conducted on August 3, 202303-08-2023
Q1FY24 Quarterly Result Announced for Neuland Laboratories Ltd.
Pharmaceuticals company Neuland Laboratories announced Q1FY24 results: Total Income of Rs 365.0 crore in Q1FY24 compared to Rs 221.7 crore in Q1FY23, up 64.7% YoY EBITDA of Rs 99.3 crore in Q1FY24 compared to Rs 29.0 crore in Q1FY23, up 242.5% YoY EBITDA margin of 27.2% in Q1FY24 compared to 13.1% in Q1FY23 , up 1,410 bps YoY PAT of Rs 62.2 crore in Q1FY24 compared to Rs 9.8 crore in Q1FY23, up 532.3% YoY PAT margin of 17.0% in Q1FY24 compared to Rs 4.4% in Q1FY23, up 1,260 bps YoY EPS (Basic) of Rs 48.5 in Q1FY24 compared to Rs 7.7 in Q1FY23, up 532.3% YoY Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “The performance this quarter is in line with our plan and is a good indicator of the business momentum within the organization. The high YoY growth had contributions from all three segments and the EBITDA margin improvement of 1,410 bps on a YoY basis reflects the change in business mix as well as operating leverage playing out. We continue to be watchful on balancing growth with profitability by having a continuous focus on cost optimization and efficient operations to capitalise on opportunities which we believe will bring us greater scale over the long term.” In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added, “CMS growth in Q1FY24 was driven by recently commercialized molecules as well as molecules in the pipeline. We expect more molecules to be commercialized in the medium term which will drive our future growth. We saw a couple of more milestones in terms of our regulatory track record as Unit 3 was successfully inspected by the US FDA and we had Unit-1 being audited by EDQM. While the external environment remains uncertain with funding of early-stage molecules being affected, we remain cautiously optimistic about our future growth given the strength of our portfolio.” Result PDF03-08-2023
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investors/Analysts Presentation on the Financial Results of the Company for the quarter ended June 30, 202303-08-2023
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on the Financial Results of the Company for the quarter ended June 30, 202303-08-2023
NEULAND LABORATORIES LTD. - 524558 - Unaudited Financial Results For Quarter Ended June 30, 2023
Unaudited Financial results for quarter ended June 30, 202303-08-2023
NEULAND LABORATORIES LTD. - 524558 - Board Meeting Outcome for Unaudited Financial Results For Quarter Ended June 30, 2023
Unaudited Financial results for quarter ended June 30, 202303-08-2023
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call Intimation Q1 FY2428-07-2023
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
Pursuant to Regulation 30 of the SEBI Listing Regulations, enclosed herewith a new set of Articles of Association of the Company duly adopted by the Members of the Company at the 39th Annual General Meeting held on July 27, 202327-07-2023